日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Long-Term Safety and Efficacy of Dupilumab Treatment in Children Aged 6 Months to 5 Years with Severe Atopic Dermatitis

Dupilumab治疗6个月至5岁重度特应性皮炎患儿的长期安全性和有效性

期刊:Pediatric Drugs
影响因子:3.3
doi:10.1007/s40272-026-00747-4
Paller, Amy S; Pinter, Andreas; Wine Lee, Lara; Aschoff, Roland; Zdybski, Jacek; Schnopp, Christina; Khokhar, Faisal A; Praestgaard, Amy H; Bansal, Ashish; Shumel, Brad; Bastian, Mike
发表日期：2026
文献求助 收藏

The Safety Data of Dupilumab for the Treatment of Moderate‑to‑Severe Atopic Dermatitis in Infants, Children, Adolescents, and Adults

Dupilumab治疗婴幼儿、儿童、青少年和成人中重度特应性皮炎的安全性数据

期刊:American Journal of Clinical Dermatology
影响因子:8.8
doi:10.1007/s40257-025-00952-w
Langley, Richard G; Gherardi, Guy; Coleman, Anna; Ardeleanu, Marius; Rodríguez-Marco, Ainara; Levy, Stephane; Bansal, Ashish; Chen, Zhen; Rossi, Ana B; Shumel, Brad; Khokhar, Faisal A
发表日期：2025
文献求助 收藏

Conjunctivitis in Adults with Atopic Dermatitis Treated with Dupilumab: An Observational Study of Clinical Characteristics, Symptomatology, and Treatment

接受度普利尤单抗治疗的成人特应性皮炎合并结膜炎：一项关于临床特征、症状和治疗的观察性研究

期刊:Advances in Therapy
影响因子:4
doi:10.1007/s12325-025-03209-4
Asbell, Penny; Akpek, Esen; Chamberlain, Winston; Chen, Zhen; Lawless, Emma; Van Spall, Michael; Ozturk, Zafer E; Shumel, Brad
结膜炎
发表日期：2025
文献求助 收藏

Immunogenicity of dupilumab in adult and pediatric patients with atopic dermatitis

度普利尤单抗在成人和儿童特应性皮炎患者中的免疫原性

期刊:Frontiers in Immunology
影响因子:5.9
doi:10.3389/fimmu.2024.1466372
Kamal, Mohamed A; Kosloski, Matthew P; Lai, Ching-Ha; Partridge, Michael A; Rajadhyaksha, Manoj; Kanamaluru, Vanaja; Bansal, Ashish; Shabbir, Arsalan; Shumel, Brad; Ardeleanu, Marius; Richards, Susan M; Yan, Hong; Xu, Christine R; Rodríguez-Marco, Ainara; Xiao, Jing; Khokhar, Faisal A; Gherardi, Guy; Babilonia, Elisa; Maloney, Jennifer; Mortensen, Eric; Akinlade, Bolanle; Braunstein, Ned; Stahl, Neil; Torri, Albert; Davis, John D; DiCioccio, A Thomas
免疫/内分泌
发表日期：2024
文献求助 收藏

Letter to the Editor Regarding 'Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab Versus Dupilumab in Moderate-to-Severe Atopic Dermatitis'

致编辑的信，关于“Lebrikizumab 与 Dupilumab 在中重度特应性皮炎中长期疗效维持和不良事件发生率的匹配调整间接比较”

期刊:Dermatology and Therapy
影响因子:4.2
doi:10.1007/s13555-024-01106-2
Bastian, Mike; Freemantle, Nick; Rossi, Ana B; Shumel, Brad; Le Bagousse, Gaelle Bego; Wang, Zhixiao; Xu, Yingxin; Guyot, Patricia
发表日期：2024
文献求助 收藏

Efficacy and Safety of Dupilumab Treatment with Concomitant Topical Corticosteroids in Children Aged 6 Months to 5 Years with Severe Atopic Dermatitis

度普利尤单抗联合局部皮质类固醇治疗6个月至5岁重度特应性皮炎患儿的疗效和安全性

期刊:Advances in Therapy
影响因子:4
doi:10.1007/s12325-023-02753-1
Paller, Amy S; Pinter, Andreas; Wine Lee, Lara; Aschoff, Roland; Zdybski, Jacek; Schnopp, Christina; Praestgaard, Amy; Bansal, Ashish; Shumel, Brad; Prescilla, Randy; Bastian, Mike
发表日期：2024
文献求助 收藏

Correction to: Efficacy and Safety of Dupilumab Treatment with Concomitant Topical Corticosteroids in Children Aged 6 Months to 5 Years with Severe Atopic Dermatitis

更正：度普利尤单抗联合局部皮质类固醇治疗6个月至5岁重度特应性皮炎患儿的疗效和安全性

期刊:Advances in Therapy
影响因子:4
doi:10.1007/s12325-024-02866-1
Paller, Amy S; Pinter, Andreas; Wine Lee, Lara; Aschoff, Roland; Zdybski, Jacek; Schnopp, Christina; Praestgaard, Amy; Bansal, Ashish; Shumel, Brad; Prescilla, Randy; Bastian, Mike
发表日期：2024
文献求助 收藏

Clinically Meaningful Responses to Dupilumab Among Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis who did Not Achieve Clear or Almost Clear Skin According to the Investigator's Global Assessment: A Post Hoc Analysis of a Phase 3 Trial

对 6 个月至 5 岁患有中重度特应性皮炎且根据研究者总体评估未达到皮肤完全清除或几乎完全清除的儿童使用度普利尤单抗治疗后，其临床意义显著的疗效：一项 3 期试验的事后分析

期刊:Acta Dermato-Venereologica
影响因子:3.7
doi:10.2340/actadv.v104.13467
Cork, Michael J; Lockshin, Benjamin; Pinter, Andreas; Chen, Zhen; Shumel, Brad; Prescilla, Randy
发表日期：2024
文献求助 收藏

Integrated Exposure-Response of Dupilumab in Children, Adolescents, and Adults With Atopic Dermatitis Using Categorical and Continuous Efficacy Assessments: A Population Analysis

采用分类和连续疗效评估方法对儿童、青少年和成人特应性皮炎患者使用度普利尤单抗进行综合暴露-反应分析：一项人群分析

期刊:Pharmaceutical Research
影响因子:4.3
doi:10.1007/s11095-023-03616-8
Briggs, Emily; Kamal, Mohamed A; Kosloski, Matthew P; Linsmeier, Ian; Jusko, Natalie; Dolphin, Nancy; Chittenden, Jason; Simpson, Eric L; Paller, Amy S; Siegfried, Elaine C; Shumel, Brad; Levit, Noah A; Bansal, Ashish; Davis, John D; Chapel, Sunny; Smith, David E; Huniti, Nidal
发表日期：2023
文献求助 收藏

Long-Term Effectiveness of Dupilumab in Patients with Atopic Dermatitis: Results up to 3 Years from the RELIEVE-AD Study

Dupilumab治疗特应性皮炎患者的长期疗效：RELIEVE-AD研究长达3年的结果

期刊:Dermatology and Therapy
影响因子:4.2
doi:10.1007/s13555-023-00965-5
Kimball, Alexa B; Delevry, Dimittri; Yang, Min; Chuang, Chien-Chia; Wang, Zhixiao; Bégo-Le-Bagousse, Gaëlle; Martins, Bruno; Wu, Eric; Shumel, Brad; Wang, Jessie; Sierka, Debra; Chao, Jingdong; Strober, Bruce
发表日期：2023
文献求助 收藏